Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788676 | 0.92 | PIK3CD (0.58) | PIK3CDLMNAHTT | |
| SCHEMBL4443357 | 0.90 | PIK3CD (0.40) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4443103 | 0.86 | LMNA (0.40) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4435660 | 0.84 | PIK3CD (0.37) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4429984 | 0.84 | PIK3CD (0.37) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4180797 | 0.84 | PIK3CD (0.55) | PIK3CDMAPK1 | |
| SCHEMBL4178120 | 0.84 | PIK3CD (0.47) | PIK3CDLMNAHTTCYP1A2CYP3A4 | |
| SCHEMBL4178301 | 0.82 | PIK3CD (0.61) | PIK3CD | |
| SCHEMBL4432954 | 0.82 | PIK3CD (0.38) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL4443536 | 0.81 | PIK3CD (0.42) | PIK3CDLMNAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2616442-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037204-A1 | INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | claimed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885LMNA 2970/4885MAPK1 205/4885 |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885LMNA 2970/4885MAPK1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.